Screener
Discontinued — last reported Q3 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Olema Pharmaceuticals, Inc.’s 10-Q, filed November 10, 2025.
- Filed
- Nov 10, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-273236
| Line item | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 |
|---|---|---|
| Operating lease liabilities | (931) | (857) |
| Net cash used in operating activities | (108,389) | (78,067) |
| Cash flows from investing activities: | ||
| Purchase of equipment | — | (159) |
| Maturities of marketable securities | 253,794 | 226,786 |
| Purchases of marketable securities | (247,370) | (205,729) |
| Net cash provided by investing activities | 6,424 | 20,898 |
| Cash flows from financing activities: |
Item 1. Financial Statements.
FAQ
- What is Olema Pharmaceuticals, Inc.'s capex?
- Olema Pharmaceuticals, Inc. (OLMA) reported capex of $0 in Q3 2025.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Olema Pharmaceuticals, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude